Vulvar cancer can be fatal, but whether it kills depends overwhelmingly on how early it is caught. When diagnosed at its earliest stage, the five-year survival rate exceeds 90%; when found at the most advanced stage, that number drops below 10%. The gap between those figures is enormous, and it reflects the reality that stage at diagnosis matters more than almost any other single factor in determining outcome. What makes vulvar cancer particularly treacherous is not its aggressiveness per se but a pattern of delayed diagnosis that pushes too many cases toward the wrong end of that survival spectrum.
Survival Rates by Stage
The clearest way to understand vulvar cancer’s lethality is to look at survival broken down by how far the disease has spread at the time of diagnosis. A large German population study found five-year relative survival rates ranging from about 92% for stage I disease all the way down to roughly 21% for stage IVB, the most advanced category.1PubMed Central. Influence of stage and age on survival of patients with vulvar cancer in Germany: a retrospective study A systematic review and meta-analysis pooling data from multiple studies reported a similar gradient: stage I patients had a five-year overall survival rate of 84%, stage II about 75%, stage III roughly 48%, and stage IV just under 10%.2PubMed. The prognostic role of FIGO stage in patients with vulvar cancer: a systematic review and meta-analysis The numbers vary somewhat between studies because of differences in population and time period, but the pattern is consistent: early-stage vulvar cancer is very survivable, while advanced disease carries a grim prognosis.
What is also concerning is that survival trends have not been moving in the right direction. Both incidence and mortality data from the United States and Canada show that overall two-year and five-year relative survival ratios have actually decreased over time, with the sharpest declines among patients aged 80 and older.3Gynecologic Oncology. Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: A population-based study Meanwhile, incidence itself has been rising. A 20-year U.S. population study covering 2000 through 2019 found a steady upward trend in age-adjusted incidence, with the increase concentrated among non-Hispanic White women.4PubMed Central. Incidence Trends of Vulvar Cancer in the United States: A 20‐Year Population‐Based Study More cases and stable or worsening survival is a troubling combination.
Why Lymph Node Status Matters So Much
If you had to pick one factor that most strongly predicts whether vulvar cancer will prove fatal, it would be whether the cancer has spread to the lymph nodes in the groin. Lymph node metastasis is consistently identified as the single most important prognostic factor for both recurrence and survival.5PubMed Central. Prognosis of vulval cancer with lymph node status and size of primary lesion: A survival study In one study, the recurrence rate was 40% in patients with positive lymph nodes compared to about 13% in those without, and survival among patients who both had positive nodes and experienced recurrence dropped to just 25%.
Long-term follow-up from a major international study confirmed this divide. Among patients whose sentinel lymph nodes tested negative for cancer, disease-specific survival at ten years was 91%. For those whose sentinel nodes were positive, it was 65%.6Gynecologic Oncology. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I Other tumor characteristics also matter. Tumor diameter, depth of invasion, and vascular invasion have all been correlated with survival, with tumor size emerging as the most important predictor in some analyses when multiple factors are considered together.7Gynecologic Oncology. Prognostic factors in carcinoma of the vulva Depth of invasion shows a clear pattern where deeper tumors correlate with worse outcomes, though its statistical significance varies across studies.8PubMed Central. Prognostic Factors for Vulvar Cancer
The Problem of Delayed Diagnosis
One of the most dangerous features of vulvar cancer is how long it can masquerade as something routine. The early symptoms, particularly itching, irritation, and skin changes, overlap with a long list of common, benign vulvar conditions. A Danish survey found that vulvar cancer patients experienced longer diagnostic delays than patients with other gynecological cancers, in part because persistent itching is so common in the general population that neither patients nor clinicians immediately flag it as a warning.9International Journal of Gynecological Cancer. Diagnostic delay experienced among gynecological cancer patients: a nationwide survey in Denmark
A German study of gynecological practices quantified just how significant these delays can be. Women diagnosed with vulvar inflammation had an average gap of 328 days before their vulvar cancer was detected. For those with noninflammatory vulvar disorders like atrophy or cysts, the average gap was about 300 days. Having a history of vulvar inflammation more than doubled the odds of a subsequent vulvar cancer diagnosis, and a history of other noninflammatory vulvar disorders raised the odds more than fivefold.10PubMed Central. Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in German gynecological practices That is close to a year of potential delay, during which a tumor that might have been caught at an early and curable stage could advance to one with a much worse prognosis.
Two Different Diseases Under One Name
Most vulvar cancers are squamous cell carcinomas, and these actually fall into two biologically distinct categories. One is driven by high-risk human papillomavirus (HPV), particularly HPV16, which accounts for roughly 85% of HPV-positive cases.11Modern Pathology. Biological relevance of human papillomaviruses in vulvar cancer HPV-positive vulvar cancers tend to occur in younger women, often under 50, and are associated with smoking and a history of vulvar precancerous lesions. These tumors typically have a warty or basaloid appearance under the microscope.12PubMed Central. A case of human papillomavirus infection and vulvar cancer in a young patient – “hit and run” theory Globally, at least about 21% of all vulvar cancers are attributable to HPV.
The other pathway, which accounts for the majority of cases, is associated with chronic skin conditions, most commonly lichen sclerosus. This is a long-standing inflammatory condition that causes thinning, scarring, and irritation of vulvar skin. In one retrospective analysis, nearly half of the women diagnosed with lichen sclerosus went on to develop vulvar cancer, and those who did tended to be significantly older at the time, with an average age at cancer onset approaching 70.13PubMed Central. Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis These HPV-independent tumors tend to appear as keratinizing squamous cell carcinomas and are more common in elderly women, which partly explains why the disease disproportionately affects older populations. Understanding which pathway produced a particular cancer matters for prevention, surveillance, and potentially treatment.
Rare Subtypes With Different Outlooks
While squamous cell carcinoma dominates, a few rarer vulvar malignancies have dramatically different survival profiles. Vulvar melanoma accounts for somewhere between 5% and 10% of vulvar cancers and carries a particularly poor prognosis.14PubMed Central. Vulvar melanoma: an analysis of prognostic factors and treatment patterns A Dutch population study found that five-year survival for vulvar melanoma improved from 37% in the 1990s to 45% in the 2000s, but even at its best it remained roughly 15% lower than for melanomas found on other skin surfaces.15Gynecologic Oncology. Rare vulvar malignancies; incidence, treatment and survival in the Netherlands Older age, larger tumor size, and advanced stage all independently predict worse outcomes for vulvar melanoma. Basal cell carcinoma of the vulva, by contrast, had a five-year relative survival of 100% in the same Dutch study, making it essentially non-lethal if treated.
How Vulvar Cancer Is Treated
Surgery remains the backbone of vulvar cancer treatment, but the operations used today look very different from those performed decades ago. Historically, treatment meant a radical vulvectomy with bilateral groin node dissection, an extensive procedure with major side effects. Over time, several modifications proved they could reduce harm without sacrificing survival: eliminating routine pelvic node dissection, using separate incisions for groin surgery, performing unilateral groin dissection for tumors confined to one side, and replacing radical vulvectomy with a more targeted wide local excision aiming for one-centimeter surgical margins.16PubMed Central. Conservative Management of Vulvar Cancer-Where Should We Draw the Line?
The most recent evolution has been the adoption of sentinel lymph node biopsy, which identifies and tests just the first nodes where cancer would drain rather than removing all groin nodes. This approach is recommended for tumors smaller than four centimeters. A U.S. population-level analysis found that sentinel node biopsy produced similar cancer-specific survival to full lymph node dissection, with a five-year vulvar cancer mortality rate of about 15% for the biopsy group compared to about 17% for the traditional surgery group.17Gynecologic Oncology. Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States This matters because full lymph node removal carries a high burden of side effects, particularly chronic leg swelling.
For locally advanced disease where surgery alone is insufficient, chemoradiation plays an important role. Adding chemotherapy to radiation has shown better overall survival, disease-specific survival, and relapse-free survival compared to radiation alone in the primary treatment setting.18International Journal of Radiation Oncology*Biology*Physics. Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva Modern dose-escalated radiation techniques using intensity-modulated delivery have pushed complete response rates higher, with one series reporting pathologic complete response in 70% of patients, and with manageable toxicity.19International Journal of Gynecological Cancer. Definitive chemoradiation or radiation therapy alone for the management of vulvar cancer
What Happens When Vulvar Cancer Comes Back
Recurrence is common. Roughly a quarter to a third of vulvar cancer patients experience a return of the disease after primary treatment. A large French multicenter study found recurrences in 30% of surgically treated patients, with a median time to recurrence of 13 months.20Journal of Gynecology Obstetrics and Human Reproduction. Patterns of first recurrence and outcomes in surgically treated women with vulvar cancer: results from FRANCOGYN study group Most recurrences were local or regional rather than distant metastases. The three-year overall survival for the entire surgically treated cohort was about 79%.
Where the recurrence appears makes a huge difference. A local recurrence on the vulva, close to where the original tumor was, can often be treated with a second wide excision and carries a cure rate of around 70%.21PubMed. Recurrent vulvar cancer Regional recurrences in the groin or pelvic lymph nodes, however, are far more dangerous and carry a high mortality rate. Distant metastases, while less common, are generally not curable with current approaches.
Immunotherapy for Advanced or Recurrent Disease
For women whose vulvar cancer has spread beyond the reach of surgery and radiation, options have historically been limited. That picture has begun to change with immunotherapy. Pembrolizumab, a checkpoint inhibitor, is now an FDA-approved option for recurrent or metastatic vulvar squamous cell carcinoma.22PubMed Central. Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines In the KEYNOTE-158 trial, which enrolled patients with previously treated advanced vulvar squamous cell carcinoma, about 11% of patients showed a measurable tumor response, and among those who did respond, the responses tended to be durable, with a median duration exceeding 20 months.23Gynecologic Oncology. Efficacy and safety of pembrolizumab in previously treated advanced vulvar squamous cell carcinoma: Results from the phase II KEYNOTE-158 study Roughly 44% of patients who had follow-up scans showed at least some tumor shrinkage.
A broader systematic review and meta-analysis of immunotherapy across nine studies found that overall response rates ranged widely, from under 6% to 75%, and median overall survival ranged from about 4 to 18 months depending on the specific treatment and patient population.24PubMed Central. Immunotherapy and Advanced Vulvar Cancer: A Systematic Review and Meta-Analysis of Survival and Safety Outcomes These are not cure rates for most patients, but they represent a genuine new option where previously there was very little. The research in this space is still young, and the evidence is thin compared to what exists for immunotherapy in other cancers.
The Role of HPV Vaccination in Prevention
Because a meaningful fraction of vulvar cancers are driven by HPV, vaccination offers a real shot at prevention. A randomized controlled trial of the quadrivalent HPV vaccine found 100% efficacy in preventing vulvar intraepithelial neoplasia caused by vaccine-targeted HPV types over four years of follow-up, with no cases in the vaccinated group versus 16 in the placebo group.25PubMed Central. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial Real-world data reinforced this: women vaccinated at age 16 or younger had roughly a 78% reduction in their risk of developing high-grade vulvar precancerous lesions or cancers compared to unvaccinated women. The benefit was smaller for those vaccinated between ages 17 and 26.26JNCI: Journal of the National Cancer Institute. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers
There is also preliminary evidence that HPV vaccination after treatment for vulvar precancerous lesions may help reduce recurrence. One prospective study found a recurrence rate of 19% in vaccinated women compared to 32% in unvaccinated women after surgical treatment for high-grade vulvar lesions, though the difference did not reach statistical significance in that relatively small study.27PubMed Central. Efficacy of HPV Vaccination Regarding Vulvar and Vaginal Recurrences in Previously Treated Women: The Need for Further Evidence Vaccination cannot prevent the roughly 79% of vulvar cancers that arise through the HPV-independent pathway, but for the HPV-related fraction, early vaccination appears to be highly effective.
Disparities in Who Gets Diagnosed Late and Who Survives
Not everyone faces the same odds with vulvar cancer. U.S. data shows that African American women are diagnosed at a younger average age (57 versus 67 for White women) but are more likely to present with distant metastatic disease (about 6% versus 4%). They also undergo surgery less frequently and receive radiation more often.28PubMed. Racial disparities and changes in clinical characteristics and survival for vulvar cancer over time Broader analyses have identified disparities tied to geography, income, and race, suggesting that access to care and timely diagnosis play significant roles in survival outcomes beyond tumor biology alone.29Journal of the American Academy of Dermatology. Impact of disease stage, treatment timing, and demographic disparities on survival in vulvar squamous cell carcinoma: Insights from a Surveillance, Epidemiology, and End Results-based analysis
Age and overall health also shape outcomes. Older patients, especially those over 80, have experienced the steepest declines in survival over time. A study examining the effects of age and comorbidity found that increasing age, higher comorbidity burden, lymph node involvement, and the type of surgery performed were all independently associated with an increased risk of death.30Gynecologic Oncology. Effect of age and comorbidity on the treatment and survival of older patients with vulvar cancer Some of this reflects the biology of aging, but some reflects treatment decisions: older patients with significant health problems may not be offered or may not tolerate the most aggressive surgical or radiation approaches.
Life After Treatment
Surviving vulvar cancer often comes with lasting physical and emotional costs that the survival statistics do not capture. The most common long-term complication is lower-limb lymphedema, chronic swelling caused by damage to or removal of groin lymph nodes. One prospective study found that by two years after diagnosis, over 90% of women treated for vulvar cancer had some evidence of lymphedema, whether self-reported swelling, a clinical diagnosis, or both. Having even mild swelling symptoms was associated with significantly lower quality of life.31Rehabilitation Oncology. The Prevalence, Incidence, and Quality-of-Life Impact of Lymphedema After Treatment for Vulvar or Vaginal Cancer The severity of lymphedema correlated with advanced age and higher body mass index, and it affected physical, cognitive, emotional, and social well-being as well as sleep and financial stability.32PubMed. Quality of life in women with vulvar cancer submitted to surgical treatment: a comparative study
Sexual functioning is another area profoundly affected. Even though surgery has become more conservative over the decades, it can still cause scarring and changes to the appearance of the external genitalia, along with damage to nerves and blood vessels involved in sexual function. Multiple studies have found that women who undergo vulvar cancer surgery are at high risk for sexual dysfunction, dissatisfaction with their intimate relationships, and psychological difficulties including depression and anxiety.33PubMed. Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: a literature review Having undergone multiple vulvar procedures and receiving adjuvant radiation both worsen these outcomes further.34PubMed Central. The Impact of Vulvar Cancer on Psychosocial and Sexual Functioning: A Literature Review These are not peripheral concerns. For many survivors, the quality of the years lived is as important as the number of them, and the conversation about vulvar cancer outcomes should include both.